Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Sep 15;25(18):5623-5637. doi: 10.1158/1078-0432.CCR-18-2207. Epub 2019 Jul 2.

PMID:
31266833
2.

Synthetic Lethal Strategy Identifies a Potent and Selective TTK and CLK1/2 Inhibitor for Treatment of Triple-Negative Breast Cancer with a Compromised G1-S Checkpoint.

Zhu D, Xu S, Deyanat-Yazdi G, Peng SX, Barnes LA, Narla RK, Tran T, Mikolon D, Ning Y, Shi T, Jiang N, Raymon HK, Riggs JR, Boylan JF.

Mol Cancer Ther. 2018 Aug;17(8):1727-1738. doi: 10.1158/1535-7163.MCT-17-1084. Epub 2018 Jun 4.

3.

CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro.

Tsuji T, Sapinoso LM, Tran T, Gaffney B, Wong L, Sankar S, Raymon HK, Mortensen DS, Xu S.

Oncotarget. 2017 Aug 18;8(43):74688-74702. doi: 10.18632/oncotarget.20342. eCollection 2017 Sep 26.

4.

Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.

Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, Miller K, Narla RK, Orlowski RZ, Raymon HK, Bjorklund CC, Thakurta A, Gandhi AK, Cathers BE, Chopra R, Daniel TO, Lopez-Girona A.

Br J Haematol. 2016 Mar;172(6):889-901. doi: 10.1111/bjh.13905. Epub 2016 Feb 23.

PMID:
26914976
5.

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Elsner J, Zhao J, Whitefield B, Tehrani L, Sapienza J, Riggs JR, Parnes JS, Papa P, Packard G, Lee BG, Harris R, Correa M, Bahmanyar S, Richardson SJ, Peng SX, Leisten J, Khambatta G, Hickman M, Gamez JC, Bisonette RR, Apuy J, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S.

J Med Chem. 2015 Jul 23;58(14):5599-608. doi: 10.1021/acs.jmedchem.5b00627. Epub 2015 Jul 8.

PMID:
26102506
6.

Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.

Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S, Correa M, Elsner J, Harris R, Lee BG, Papa P, Parnes JS, Riggs JR, Sapienza J, Tehrani L, Whitefield B, Apuy J, Bisonette RR, Gamez JC, Hickman M, Khambatta G, Leisten J, Peng SX, Richardson SJ, Cathers BE, Canan SS, Moghaddam MF, Raymon HK, Worland P, Narla RK, Fultz KE, Sankar S.

J Med Chem. 2015 Jul 9;58(13):5323-33. doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26.

PMID:
26083478
7.

CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.

Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S, Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam MF, Canan SS, Worland P, Sankar S, Raymon HK.

Mol Cancer Ther. 2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8.

8.

An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.

Carrancio S, Markovics J, Wong P, Leisten J, Castiglioni P, Groza MC, Raymon HK, Heise C, Daniel T, Chopra R, Sung V.

Br J Haematol. 2014 Jun;165(6):870-82. doi: 10.1111/bjh.12838. Epub 2014 Mar 18.

9.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

10.

1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4.

Ruchelman AL, Man HW, Chen R, Liu W, Lu L, Cedzik D, Zhang L, Leisten J, Collette A, Narla RK, Raymon HK, Muller GW.

Bioorg Med Chem. 2011 Nov 1;19(21):6356-74. doi: 10.1016/j.bmc.2011.08.068. Epub 2011 Sep 5.

PMID:
21955454
11.

The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.

Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.

Cancer Res. 2006 Jan 15;66(2):951-9.

12.

Emerging treatments for asthma.

Blease K, Lewis A, Raymon HK.

Expert Opin Emerg Drugs. 2003 May;8(1):71-81. Review.

PMID:
14610913
13.
14.

Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.

Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P.

J Biol Chem. 2002 Oct 11;277(41):38884-94. Epub 2002 Jul 26.

15.

Immortalized human dorsal root ganglion cells differentiate into neurons with nociceptive properties.

Raymon HK, Thode S, Zhou J, Friedman GC, Pardinas JR, Barrere C, Johnson RM, Sah DW.

J Neurosci. 1999 Jul 1;19(13):5420-8.

16.

Application of ex vivo gene therapy in the treatment of Parkinson's disease.

Raymon HK, Thode S, Gage FH.

Exp Neurol. 1997 Mar;144(1):82-91. Review. Erratum in: Exp Neurol. 2003 Apr;25(3):I.

PMID:
9126156
17.

Expression of alpha 2 adrenoceptors during rat brain development--II. Alpha 2C messenger RNA expression and [3H]rauwolscine binding.

Winzer-Serhan UH, Raymon HK, Broide RS, Chen Y, Leslie FM.

Neuroscience. 1997 Jan;76(1):261-72.

PMID:
8971776
18.

Expression of alpha 2 adrenoceptors during rat brain development--I. Alpha 2A messenger RNA expression.

Winzer-Serhan UH, Raymon HK, Broide RS, Chen Y, Leslie FM.

Neuroscience. 1997 Jan;76(1):241-60.

PMID:
8971775
19.

Regional differences in responsiveness of adult CNS axons to grafts of cells expressing human neurotrophin 3.

Senut MC, Tuszynski MH, Raymon HK, Suhr ST, Liou NH, Jones KR, Reichardt LF, Gage FH.

Exp Neurol. 1995 Sep;135(1):36-55.

PMID:
7556552
20.

Generation and culturing of precursor cells and neuroblasts from embryonic and adult central nervous system.

Ray J, Raymon HK, Gage FH.

Methods Enzymol. 1995;254:20-37. No abstract available.

PMID:
8531687
21.

Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease.

Takayama H, Ray J, Raymon HK, Baird A, Hogg J, Fisher LJ, Gage FH.

Nat Med. 1995 Jan;1(1):53-8.

PMID:
7584953
22.
23.

Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease.

Fisher LJ, Raymon HK, Gage FH.

Ann N Y Acad Sci. 1993 Sep 24;695:278-84. Review.

PMID:
8239296
25.

Epidermal growth factor and basic fibroblast growth factor: effects on an overlapping population of neocortical neurons in vitro.

Kornblum HI, Raymon HK, Morrison RS, Cavanaugh KP, Bradshaw RA, Leslie FM.

Brain Res. 1990 Dec 10;535(2):255-63.

PMID:
2073605

Supplemental Content

Loading ...
Support Center